Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication

Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.

Blue targets and three arrows reaching the center of the first one
Libtayo joins a competitive field with a new lung cancer indication • Source: Shutterstock (Shutterstock)

Sanofi and Regeneron Pharmaceuticals, Inc. were late to market with their PD-1 inhibitor Libtayo (cemiplimab-rwlc), but they have won a coveted approval from the US Food and Drug Administration for the first-line treatment of advanced non-small cell lung cancer (NSCLC) as a monotherapy, joining only Merck & Co., Inc.'s Keytruda (pembrolizumab) and Roche Holding AG's Tecentriq (atezolizumab) with that specific indication.

The commercial opportunity is considered a significant one in the field of cancer, but Merck's Keytruda has emerged as the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer